Yoshio Katamura
Overview
Explore the profile of Yoshio Katamura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
711
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Furuse J, Izumi N, Motomura K, Inaba Y, Katamura Y, Kondo Y, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941845
Background/objectives: The real-world survival of patients with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib has been explored retrospectively with a small sample size. We conducted a prospective observational 2-year extension...
2.
Furuse J, Izumi N, Motomura K, Inaba Y, Katamura Y, Kondo Y, et al.
Drugs Real World Outcomes
. 2023 Jan;
10(2):195-205.
PMID: 36602748
Background: Lenvatinib was approved for use in unresectable hepatocellular carcinoma (uHCC) in Japan in 2018. Patients with diverse clinical characteristics receive lenvatinib treatment in clinical practice. Thus, it is crucial...
3.
Nishimura T, Onogawa S, Yamamoto T, Okuda Y, Ikeda M, Matsumoto N, et al.
DEN Open
. 2022 Jul;
3(1):e137.
PMID: 35898845
The Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine is extensively used worldwide, and its safety has been proven. Herein, we report a case of an acute necrotic disorder in the small...
4.
Yamamoto T, Abe T, Oshita A, Yonehara S, Katamura Y, Matsumoto N, et al.
Surg Case Rep
. 2020 Oct;
6(1):264.
PMID: 33026548
Background: Intrahepatic cholangiocarcinoma (ICC) is the second most common malignancy of primary liver cancer. Among the several pathological types of ICC, only five cases of the clear cell type have...
5.
Ohya K, Imamura M, Teraoka Y, Morio K, Fujino H, Nakahara T, et al.
Hepatol Res
. 2020 Sep;
50(11):1234-1243.
PMID: 32914512
Aim: Combination therapy with sofosbuvir (SOF) plus velpatasvir (VEL) is approved for patients with hepatitis C virus (HCV)-related decompensated cirrhosis. We analyzed the real-world efficacy of SOF/VEL therapy. Methods: Thirty-three...
6.
Izumi Y, Hanada K, Okazaki A, Minami T, Hirano N, Ikemoto J, et al.
Endosc Int Open
. 2019 Apr;
7(4):E585-E593.
PMID: 30993162
No abstract available.
7.
Morio K, Imamura M, Kawakami Y, Nakamura Y, Hatooka M, Morio R, et al.
J Med Virol
. 2018 Jul;
90(12):1834-1840.
PMID: 30016555
Background: Sustained virological response (SVR) rates for the treatment of chronic hepatitis C virus (HCV)-infected patients have drastically improved with the use of direct-acting antiviral (DAA) therapies; however, a small...
8.
Hatooka M, Kawaoka T, Aikata H, Inagaki Y, Morio K, Nakahara T, et al.
BMC Cancer
. 2018 Jun;
18(1):633.
PMID: 29866075
Background: In patients with advanced hepatocellular carcinoma (HCC), evidence is unclear as to whether hepatic arterial infusion chemotherapy (HAIC) or sorafenib is superior. We performed a prospective, open-label, non-comparative phase...
9.
Kawakami Y, Ochi H, Hayes C, Imamura M, Tsuge M, Nakahara T, et al.
J Gastroenterol
. 2017 Aug;
53(4):548-556.
PMID: 28815329
Background: In Japan, daclatasvir (DCV) and asunaprevir (ASV) therapy was the first IFN-free treatment to be approved, and thousands of patients have since been successfully treated, with an SVR rate...
10.
Suda G, Furusyo N, Toyoda H, Kawakami Y, Ikeda H, Suzuki M, et al.
J Gastroenterol
. 2017 Jun;
53(1):119-128.
PMID: 28560477
Background: Hepatitis C virus (HCV) infection is common in hemodialysis patients and worsens their prognosis, while antiviral therapy options are limited. Recently, clinical trial and real-world, small-scale studies have reported...